List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1156289/publications.pdf Version: 2024-02-01



TVDEE H KISED

#	Article	IF	CITATIONS
1	Management of Extravasation Injuries: A Focused Evaluation of Noncytotoxic Medications. Pharmacotherapy, 2014, 34, 617-632.	2.6	113
2	Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement. Clinical Pharmacokinetics, 2015, 54, 783-795.	3.5	107
3	A Randomized, Double-Blind, Placebo-Controlled Dose Range Study of Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal*. Critical Care Medicine, 2014, 42, 1131-1139.	0.9	94
4	Erythromycin vs Metoclopramide for Facilitating Gastric Emptying and Tolerance to Intragastric Nutrition in Critically III Patients. Journal of Parenteral and Enteral Nutrition, 2008, 32, 412-419.	2.6	90
5	Evaluation of Bivalirudin Treatment for Heparin-Induced Thrombocytopenia in Critically III Patients with Hepatic and/or Renal Dysfunction. Pharmacotherapy, 2006, 26, 452-460.	2.6	82
6	African Americans Are Less Likely to Receive Care by a Cardiologist During anÂIntensive Care Unit Admission for HeartÂFailure. JACC: Heart Failure, 2018, 6, 413-420.	4.1	81
7	Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrology Dialysis Transplantation, 2005, 20, 1813-1820.	0.7	75
8	Gastric Motility Function in Critically III Patients TolerantvsIntolerant to Gastric Nutrition. Journal of Parenteral and Enteral Nutrition, 2008, 32, 45-50.	2.6	72
9	Outcomes Associated with Corticosteroid Dosage in Critically III Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1052-1064.	5.6	72
10	Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. Critical Care, 2015, 19, 32.	5.8	72
11	Safety, Efficacy, and Dosing Requirements of Bivalirudin in Patients with Heparin-Induced Thrombocytopenia. Pharmacotherapy, 2008, 28, 1115-1124.	2.6	71
12	Half-Dose Versus Full-Dose Alteplase for Treatment of Pulmonary Embolism*. Critical Care Medicine, 2018, 46, 1617-1625.	0.9	71
13	Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study. Annals of Clinical Microbiology and Antimicrobials, 2017, 16, 60.	3.8	54
14	Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 423-428.	1.7	52
15	Systemic Anticoagulation Considerations in Chronic Kidney Disease. Advances in Chronic Kidney Disease, 2010, 17, 420-427.	1.4	51
16	Propylene Glycol Accumulation in Critically III Patients Receiving Continuous Intravenous Lorazepam Infusions. Annals of Pharmacotherapy, 2009, 43, 1964-1971.	1.9	50
17	Comparison of the aPTT With Alternative Tests for Monitoring Direct Thrombin Inhibitors in Patient Samples. American Journal of Clinical Pathology, 2014, 141, 665-674.	0.7	45
18	Evaluation of Diagnostic Tests and Argatroban or Lepirudin Therapy in Patients with Suspected Heparin-Induced Thrombocytopenia. Pharmacotherapy, 2005, 25, 1736-1745.	2.6	43

#	Article	IF	CITATIONS
19	A Randomized, Double-Blind Pilot Study of Dexmedetomidine Versus Midazolam for Intensive Care Unit Sedation. Journal of Intensive Care Medicine, 2015, 30, 167-175.	2.8	41
20	An Observational Study of the Efficacy of Cisatracurium Compared with Vecuronium in Patients with or at Risk for Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 897-904.	5.6	41
21	Levofloxacin Pharmacokinetics and Pharmacodynamics in Patients with Severe Burn Injury. Antimicrobial Agents and Chemotherapy, 2006, 50, 1937-1945.	3.2	39
22	Outcomes of ICU Patients With a Discharge Diagnosis of Critical Illness Polyneuromyopathy: A Propensity-Matched Analysis. Critical Care Medicine, 2017, 45, 2055-2060.	0.9	39
23	Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus. Journal of Thrombosis and Thrombolysis, 2021, 52, 517-522.	2.1	36
24	Adjunctive Dexmedetomidine Therapy in the Intensive Care Unit: A Retrospective Assessment of Impact on Sedative and Analgesic Requirements, Levels of Sedation and Analgesia, and Ventilatory and Hemodynamic Parameters. Pharmacotherapy, 2007, 27, 351-359.	2.6	35
25	Intraventricular Daptomycin and Intravenous Linezolid for the Treatment of External Ventricular-Drain–Associated Ventriculitis Due to Vancomycin-Resistant Enterococcus faecium. Annals of Pharmacotherapy, 2012, 46, 1722-1722.	1.9	33
26	Noninvasive Ventilation Use in Critically III Patients with Acute Asthma Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1520-1530.	5.6	33
27	Evaluation of Early Dexmedetomidine Addition to the Standard of Care for Severe Alcohol Withdrawal in the ICU. Journal of Intensive Care Medicine, 2016, 31, 198-204.	2.8	31
28	Efflux Pump Contribution to Multidrug Resistance in Clinical Isolates of <i>Pseudomonas aeruginosa</i> . Pharmacotherapy, 2010, 30, 632-638.	2.6	28
29	Perceived Motivating Factors and Barriers for the Completion of Postgraduate Training Among American Pharmacy Students Prior to Beginning Advanced Pharmacy Practice Experiences. American Journal of Pharmaceutical Education, 2017, 81, 90.	2.1	28
30	Treatment of Hepatorenal Syndrome. Pharmacotherapy, 2009, 29, 1196-1211.	2.6	25
31	Evaluation of empiric versus nomogramâ€based direct thrombin inhibitor management in patients with suspected heparinâ€induced thrombocytopenia. American Journal of Hematology, 2011, 86, 267-272.	4.1	25
32	Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961989661.	1.7	24
33	Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care. International Journal of Antimicrobial Agents, 2021, 57, 106310.	2.5	24
34	Bivalirudin versus Unfractionated Heparin for Prevention of Hemofilter Occlusion During Continuous Renal Replacement Therapy. Pharmacotherapy, 2010, 30, 1117-1126.	2.6	23
35	The Effectiveness of a Vancomycin Dosing Guideline in the Neonatal Intensive Care Unit for Achieving Goal Therapeutic Trough Concentrations. Journal of Clinical Pharmacology, 2019, 59, 997-1005.	2.0	23
36	Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients. Journal of Thrombosis and Thrombolysis, 2020, 49, 259-267.	2.1	21

#	Article	IF	CITATIONS
37	Gender inequity and sexual harassment in the pharmacy profession: Evidence and call to action. American Journal of Health-System Pharmacy, 2021, 78, 2059-2076.	1.0	21
38	Antithrombotic Therapy in Patients With Thrombocytopenic Cancer. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 799-806.	1.7	20
39	The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. Clinical Transplantation, 2014, 28, 590-597.	1.6	20
40	Hydroxocobalamin Versus Methylene Blue for Vasoplegic Syndrome in Cardiothoracic Surgery: A Retrospective Cohort. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, 1763-1770.	1.3	20
41	Continuous infusion vs intermittent vancomycin in neurosurgical intensive care unit patients. Journal of Critical Care, 2015, 30, 1153.e1-1153.e6.	2.2	18
42	Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center. Annals of Clinical Microbiology and Antimicrobials, 2019, 18, 13.	3.8	18
43	Proposed Revision to the Existing Specialty and Specialist Certification Framework for Pharmacy Practitioners. Pharmacotherapy, 2009, 29, 489-489.	2.6	17
44	Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin. Clinical Pharmacokinetics, 2022, 61, 363-374.	3.5	17
45	Management of intracerebral hemorrhage – use of statins. Vascular Health and Risk Management, 2016, 12, 153.	2.3	16
46	660: EXTENDED-DURATION VERSUS STANDARD-DURATION OSELTAMIVIR IN CRITICALLY ILL PATIENTS WITH INFLUENZA. Critical Care Medicine, 2018, 46, 316-316.	0.9	16
47	Evaluation of valganciclovir pharmacokinetics in lung transplant recipients. Journal of Heart and Lung Transplantation, 2012, 31, 159-166.	0.6	15
48	Cerebral Vasospasm in Critically III Patients with Aneurysmal Subarachnoid Hemorrhage: Does the Evidence Support the Ever-Growing List of Potential Pharmacotherapy Interventions?. Hospital Pharmacy, 2014, 49, 923-941.	1.0	15
49	A survey of prescriber perceptions about the prevention of stress-related mucosal bleeding in the intensive care unit. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 658-662.	1.5	15
50	Proton pump inhibitors and histamine-2 receptor antagonists in the intensive care setting: focus on therapeutic and adverse events. Expert Opinion on Drug Safety, 2015, 14, 269-280.	2.4	14
51	Evaluation of Prophylactic Heparin Dosage Strategies and Risk Factors for Venous Thromboembolism in the Critically III Patient. Pharmacotherapy, 2019, 39, 232-241.	2.6	14
52	Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110390.	1.7	14
53	Weight-based versus set dosing of vancomycin for coronary artery bypass grafting or aortic valve surgery. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 1925-1930.	0.8	13
54	Patient nonadherence to filling discharge medication prescriptions from the emergency department: Barriers and clinical implications. American Journal of Health-System Pharmacy, 2018, 75, 316-320.	1.0	13

#	Article	IF	CITATIONS
55	Levetiracetam Pharmacokinetics in a Patient with Intracranial Hemorrhage Undergoing Continuous Veno-Venous Hemofiltration. American Journal of Case Reports, 2017, 18, 458-462.	0.8	13
56	Association Between Vasopressin Rebranding and Utilization in Patients With Septic Shock*. Critical Care Medicine, 2022, 50, 644-654.	0.9	13
57	Severe acute exacerbations of chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine, 2015, 21, 142-148.	2.6	12
58	Research Fellowship Programs as a Pathway for Training Independent Clinical Pharmacy Scientists. Pharmacotherapy, 2015, 35, e13-e19.	2.6	12
59	Evaluation of Sulfobutylether-β-Cyclodextrin Exposure in a Critically III Patient Receiving Intravenous Posaconazole While Undergoing Continuous Venovenous Hemofiltration. Antimicrobial Agents and Chemotherapy, 2015, 59, 6653-6656.	3.2	12
60	Calcineurin Inhibitor and Nonsteroidal Antiâ€inflammatory Drug Interaction: Implications of Changes in Renal Function Associated With Concurrent Use. Journal of Clinical Pharmacology, 2018, 58, 1443-1451.	2.0	12
61	A Randomized Pharmacokinetic and Pharmacodynamic Evaluation of Every 8â€Hour and 12â€Hour Dosing Strategies of Vancomycin and Cefepime in Neurocritically ill Patients. Pharmacotherapy, 2018, 38, 921-934.	2.6	12
62	Patterns of utilization and effects of hospital-specific factors on physical, occupational, and speech therapy for critically ill patients with acute respiratory failure in the USA: results of a 5-year sample. Critical Care, 2019, 23, 175.	5.8	12
63	Use of a Cholestyramine Washout in a Patient With Septic Shock on Leflunomide Therapy. Journal of Intensive Care Medicine, 2016, 31, 412-414.	2.8	11
64	Stability of acetylcysteine solution repackaged in oral syringes and associated cost savings. American Journal of Health-System Pharmacy, 2007, 64, 762-766.	1.0	10
65	Neuromuscular Blockade Resistance During Therapeutic Hypothermia. Annals of Pharmacotherapy, 2011, 45, 418-418.	1.9	10
66	Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer. Journal of Thrombosis and Haemostasis, 2018, 16, 2492-2500.	3.8	10
67	Comparative Effectiveness of Direct Oral Anticoagulants and Warfarin for the Treatment of Left Ventricular Thrombus. Journal of Cardiac Failure, 2019, 25, S26-S27.	1.7	10
68	Impact of Macrolide Antibiotics on Hospital Readmissions and Other Clinically Important Outcomes in Critically III Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Propensity Score–Matched Cohort Study. Pharmacotherapy, 2019, 39, 242-252.	2.6	10
69	A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Clutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab. American Journal of Case Reports, 2021, 22, e931702.	0.8	10
70	Principles of Kidney Pharmacotherapy for the Nephrologist: Core Curriculum 2021. American Journal of Kidney Diseases, 2021, 78, 442-458.	1.9	10
71	Pharmacokinetic Evaluation of Cefazolin in the Cerebrospinal Fluid of Critically III Patients. Open Forum Infectious Diseases, 2022, 9, ofab649.	0.9	10
72	Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2022, 54, 276-286.	2.1	10

#	Article	IF	CITATIONS
73	Azole-Resistant Aspergillus and Echinocandin-Resistant Candida: What Are the Treatment Options?. Current Fungal Infection Reports, 2020, 14, 141-152.	2.6	9
74	Evaluation of Systemic Corticosteroids in Patients With an Acute Exacerbation of COPD and a Diagnosis of Pneumonia. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2018, 5, 57-65.	0.7	9
75	Stability of phenylephrine hydrochloride injection in polypropylene syringes. American Journal of Health-System Pharmacy, 2007, 64, 1092-1095.	1.0	8
76	Correlation of Pharmacokinetic/Pharmacodynamic–Derived Predictions of Antibiotic Efficacy with Clinical Outcomes in Severely III Patients with <i>Pseudomonas aeruginosa</i> Pneumonia. Pharmacotherapy, 2013, 33, 1022-1034.	2.6	8
77	Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	8
78	Prefilter Bivalirudin for Preventing Hemofilter Occlusion in Continuous Renal Replacement Therapy. Annals of Pharmacotherapy, 2009, 43, 1360-1365.	1.9	7
79	An overview of current and emerging antifungal pharmacotherapy for invasive fungal infections. Expert Opinion on Pharmacotherapy, 2021, 22, 1355-1371.	1.8	7
80	Evaluation of Phenylephrine Stability in Polyvinyl Chloride Bags. Hospital Pharmacy, 2014, 49, 455-457.	1.0	6
81	Stability of dronabinol capsules when stored frozen, refrigerated, or at room temperature. American Journal of Health-System Pharmacy, 2016, 73, 1088-1092.	1.0	6
82	Thiocyanate Accumulation in Critically III Patients Receiving Nitroprusside Infusions. Journal of Intensive Care Medicine, 2017, 32, 547-553.	2.8	5
83	Antithrombin Administration During Intravenous Heparin Anticoagulation in the Intensive Care Unit: A Single-Center Matched Retrospective Cohort Study. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 145-150.	1.7	5
84	Extrapolating Antifungal Animal Data to Humans—Is It Reliable?. Current Fungal Infection Reports, 2020, 14, 50-62.	2.6	5
85	High-Dose Versus Low-Dose Systemic Steroids in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Systematic Review. Chronic Obstructive Pulmonary Diseases (Miami,) Tj ETQq1 I	l 00 78 431	4 æBT /Over
86	Pharmacist and Physician Collaborative Practice Model Improves Vancomycin Dosing in an Intensive Care Unit. International Journal of Clinical Medicine, 2016, 07, 675-684.	0.2	5
87	656: EVALUATION OF HIGH-DOSE VERSUS STANDARD-DOSE OSELTAMIVIR IN CRITICALLY ILL PATIENTS WITH INFLUENZA. Critical Care Medicine, 2018, 46, 314-314.	0.9	4
88	Cancer-associated thromboembolism: antithrombotic management of hospitalized patients. Journal of Thrombosis and Thrombolysis, 2020, 49, 59-66.	2.1	4
89	A Survey of Corticosteroid Dosing for Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Assisted Ventilation. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2017, 4, 186-193.	0.7	4
90	Extended Stability of Epinephrine Hydrochloride Injection in Polyvinyl Chloride Bags Stored in Amber Ultraviolet Light–Blocking Bags. Hospital Pharmacy, 2017, 52, 570-573.	1.0	3

TYREE H KISER

#	Article	IF	CITATIONS
91	903. Critical Care Medicine, 2019, 47, 430.	0.9	3
92	Impact of a <scp>pharmacistâ€inclusive postâ€discharge</scp> clinic on outcomes in heart failure patients with reduced ejection fraction: Rates of hospital readmission, emergency department visits, or death. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 1516-1523.	1.0	3
93	Correlation of antimicrobial fraction unbound and sieving coefficient in critically ill patients on continuous renal replacement therapy: a systematic review. Journal of Antimicrobial Chemotherapy, 2022, 77, 310-319.	3.0	3
94	Reliability and accuracy of practitioner-calculated Acute Physiology and Chronic Health Evaluation II scores for determining the appropriateness of drotrecogin alfa (activated). American Journal of Health-System Pharmacy, 2010, 67, 136-143.	1.0	2
95	Managing the Intravenous Calcium Shortage: Evaluation of Calcium Chloride Stability in 0.9% Sodium Chloride and Dextrose 5% Water Polyvinyl Chloride Bags. Hospital Pharmacy, 2012, 47, 27-30.	1.0	2
96	Key Articles and Guidelines in the Management of Pulmonary Arterial Hypertension: 2011 Update. Pharmacotherapy, 2012, 32, e134-e169.	2.6	2
97	Pharmacologic Options for Prevention and Management of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage. Hospital Pharmacy, 2013, 48, S2-S9.	1.0	2
98	Critical care essentials for pharmacy trainees and new clinical practitioners. American Journal of Health-System Pharmacy, 2021, 78, 1176-1183.	1.0	2
99	Gender inequity and sexual harassment in the pharmacy profession: Evidence and call to action executive summary. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 1375-1378.	1.0	2
100	Pros and Cons of Extrapolating Animal Data on Antifungal Pharmacodynamics to Humans. Current Fungal Infection Reports, 2011, 5, 59-66.	2.6	1
101	425. Critical Care Medicine, 2013, 41, A102-A103.	0.9	1
102	732. Critical Care Medicine, 2013, 41, A181.	0.9	1
103	Five years of lesson modification to implement non-traditional learning sessions in a traditional-delivery curriculum: A retrospective assessment using applied implementation variables. Currents in Pharmacy Teaching and Learning, 2017, 9, 237-245.	1.0	1
104	Divergent humoral responses to 23-valent pneumococcal polysaccharide vaccine in critically-ill burn and neurosurgical patients. PLoS ONE, 2018, 13, e0197037.	2.5	1
105	Ribavirin and cellular ribavirinâ€ŧriphosphate concentrations in blood and bronchoalveolar lavage fluid in two lung transplant patients with respiratory syncytial virus. Transplant Infectious Disease, 2021, 23, e13464.	1.7	1
106	935. Critical Care Medicine, 2012, 40, 1-328.	0.9	1
107	Hepatorenal Syndrome. International Journal of Clinical Medicine, 2014, 05, 102-110.	0.2	1
108	Pharmacologic Options for Prevention and Management of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage. Hospital Pharmacy, 2013, 48, S2-S9.	1.0	1

#	Article	IF	CITATIONS
109	Stability of Ribavirin for Inhalation Packaged in Syringes or Glass Vials when Stored Frozen, Refrigerated, and at Room Temperature. International Journal of Pharmaceutical Compounding, 2016, 20, 521-525.	0.0	1
110	The CYP3A Enzyme Inhibitor Diltiazem, Rather Than Genetic Polymorphisms, Is Associated with Everolimus Concentrations in Lung Transplant Recipients. Journal of Heart and Lung Transplantation, 2013, 32, S295-S296.	0.6	0
111	A Randomized, Double-Blind, Placebo-Controlled Dose Range Study of Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal. Critical Care Medicine, 2014, 42, e609.	0.9	0
112	997: NATIONAL SURVEY OF PHARMACY STUDENTS' OPINIONS OF CRITICAL CARE PHARMACISTS' ROLES/RESPONSIBILITIES. Critical Care Medicine, 2018, 46, 482-482.	0.9	0
113	921: EVALUATION OF UFH VERSUS LMWH FOR PHARMACOLOGIC THROMBOPROPHYLAXIS IN PATIENTS WITH CANCER. Critical Care Medicine, 2018, 46, 444-444.	0.9	0
114	The authors reply. Critical Care Medicine, 2018, 46, e347-e348.	0.9	0
115	The authors reply. Critical Care Medicine, 2018, 46, e1224-e1225.	0.9	0
116	EVALUATION OF LEVOFLOXACIN PHARMACOKINETICS IN PATIENTS WITH SEVERE BURN INJURY Critical Care Medicine, 2005, 33, A172.	0.9	0
117	ERYTHROMYCIN VS. METOCLOPRAMIDE FOR FACILITATING GASTRIC EMPTYING AND TOLERANCE TO INTRAGASTRIC NUTRITION Critical Care Medicine, 2005, 33, A97.	0.9	0
118	1134: Evaluation of Parenteral Lidocaine for Nephrolithiasis-Induced Renal Colic in the ED. Critical Care Medicine, 2021, 49, 569-569.	0.9	0
119	Formulary Substitution of Proton Pump Inhibitors Based on Acquisition Price: Changes in Usage and Costs of Acid-Suppressant Therapies. P and T, 2006, 31, 716-734.	0.9	0
120	Evaluation of Insulin Infusion Rates for the Treatment of Diabetic Ketoacidosis in the Emergency Department. Journal of Biosciences and Medicines, 2022, 10, 203-211.	0.2	0
121	700: CORRELATION OF ANTIMICROBIAL FRACTION UNBOUND AND CRRT SIEVING COEFFICIENT: A SYSTEMATIC REVIEW. Critical Care Medicine, 2022, 50, 344-344.	0.9	0
122	924: PHARMACODYNAMIC EVALUATION OF VARYING ALTEPLASE DOSAGES FOR THE TREATMENT OF PULMONARY EMBOLISM. Critical Care Medicine, 2022, 50, 459-459.	0.9	0
123	Correlation Between and Nursing Satisfaction With CIWA-Ar, mMINDS, and SEWS Scoring Tools for the Assessment of Severe Alcohol Withdrawal Syndrome in ICU Patients. Annals of Pharmacotherapy, 0, , 106002802211025.	1.9	0
124	Why So Salty? Transient Diabetes Insipidus After Discontinuation of Vasopressin. , 2022, 1, .		0